A case report from 2026 documents a patient with familial lecithin-cholesterol acyltransferase deficiency (FLD), a rare genetic disorder, who experienced progressive kidney failure over 10 years despite treatment with diet and medications. According to Gram Research analysis, as kidney function declined, the patient developed serious complications including heart valve disease, heart rhythm problems, heart failure, and stroke. Once dialysis began, the patient’s treatment-resistant anemia rapidly improved, suggesting dialysis removes toxic substances that accumulate in advanced kidney disease.
A case report from 2026 describes a patient with a rare inherited condition called familial lecithin-cholesterol acyltransferase deficiency (FLD), caused by a specific genetic mutation. Over 10 years, the patient experienced progressive kidney damage that eventually required dialysis, along with serious complications affecting the heart, blood vessels, and brain. The case shows how this genetic disorder affects multiple body systems and suggests that doctors need to monitor patients closely as their kidney function declines. Understanding this rare disease helps doctors recognize warning signs and manage complications more effectively.
Key Statistics
A 2026 case report documented a patient with familial lecithin-cholesterol acyltransferase deficiency who experienced progressive kidney failure over 10 years, eventually requiring dialysis and developing multiple cardiovascular and neurological complications.
In this FLD case report, the patient’s anemia, which had been resistant to erythropoietin treatment, rapidly improved after dialysis initiation, suggesting that dialysis effectively removes uremic toxins that interfere with red blood cell production.
The case report shows that dietary restriction and renin-angiotensin system blockade provided initial stabilization of kidney function in FLD, but this protective effect was temporary, with kidney function continuing to decline despite continued management.
The Quick Take
- What they studied: How a rare genetic disease called familial lecithin-cholesterol acyltransferase deficiency (FLD) progresses over many years and what complications develop as kidney function gets worse.
- Who participated: One patient with a confirmed genetic mutation (Cys74Tyr) who was followed by doctors for more than 10 years as their condition developed.
- Key finding: The patient’s kidneys gradually failed over a decade despite treatment with diet changes and blood pressure medications. As kidney function worsened, serious complications developed in the heart, blood vessels, and brain, eventually requiring dialysis.
- What it means for you: This case helps doctors recognize that FLD is a serious condition affecting multiple body systems. If you have a family history of kidney disease, anemia, or eye problems, genetic testing may be important. This research is mainly relevant to people with this rare genetic condition and their doctors.
The Research Details
This is a case report, which means doctors documented the medical history and treatment of a single patient with a rare genetic disease over 10 years. The patient had a confirmed genetic mutation that causes familial lecithin-cholesterol acyltransferase deficiency (FLD). Doctors tracked how the disease progressed, what treatments were tried, and what complications developed over time.
The patient initially received treatment with a special diet (low in fat and protein) and medications that block the renin-angiotensin system, which helps protect kidneys. Doctors monitored kidney function, blood work, and symptoms regularly. As the disease progressed, additional complications emerged, which doctors documented carefully.
This type of study is valuable for rare diseases because they occur so infrequently that large research studies are difficult to conduct. By carefully documenting one patient’s experience, doctors can learn about disease patterns and help other patients with the same condition.
Case reports are especially important for rare genetic diseases where few patients exist. This detailed documentation helps doctors around the world recognize FLD earlier and understand what to expect as the disease progresses. It also shows which treatments work and which complications are most likely to develop, helping doctors provide better care.
This is a single case report, which is the lowest level of research evidence. However, the patient’s genetic mutation was confirmed through testing, and the observations were made by medical professionals over a long period. The main limitation is that findings from one patient cannot be automatically applied to all patients with FLD, as genetic diseases can vary between individuals. The case is valuable for generating hypotheses and helping doctors recognize similar patterns in other patients.
What the Results Show
The patient with FLD showed a 10-year disease course with distinct phases. Initially, the patient presented with the classic signs of FLD: cloudy corneas (eye problems), anemia (low red blood cells), and protein in the urine. Kidney function gradually declined over several years.
When doctors started the patient on a restricted diet and kidney-protective medications, kidney function temporarily stabilized. However, this improvement did not last. The patient’s kidney function continued to decline despite ongoing treatment, eventually requiring dialysis (artificial kidney treatment).
As kidney function worsened, serious complications developed in multiple body systems. The patient developed aortic valve stenosis (narrowing of a heart valve), complete atrioventricular block (a serious heart rhythm problem), heart failure, and cerebellar infarction (stroke in the brain). These complications appeared to develop around the same time that kidney function was declining most rapidly.
Once the patient started dialysis, an interesting improvement occurred: the anemia that had been resistant to treatment with erythropoietin (a hormone that stimulates red blood cell production) rapidly improved. This suggests that dialysis helped remove toxic substances that were interfering with red blood cell production.
The temporal relationship between worsening kidney function and the development of cardiovascular (heart and blood vessel) and neurovascular (brain blood vessel) complications is noteworthy. This suggests that as kidneys fail, toxic substances accumulate in the blood that can damage the heart and brain. The rapid improvement in anemia after dialysis initiation demonstrates that dialysis can effectively remove some of these harmful substances. The case also shows that dietary management and blood pressure medications, while helpful initially, have limits in slowing disease progression in FLD.
Previous research on FLD has focused mainly on early disease stages, particularly the kidney involvement and the classic triad of corneal opacity, anemia, and proteinuria. This case report extends knowledge by documenting the long-term progression beyond 10 years and highlighting the emergence of cardiovascular and neurological complications. Earlier case reports described kidney failure in FLD, but this case provides detailed documentation of multiple systemic complications occurring simultaneously with advanced renal disease, which is less commonly reported in the literature.
This is a single case report involving one patient, so the findings cannot be generalized to all patients with FLD. Genetic diseases can vary significantly between individuals, even with the same mutation. The patient’s specific response to treatment and complications may not be typical. Additionally, case reports lack a comparison group, so it’s unclear whether the complications observed were directly caused by FLD or influenced by other factors. The case provides valuable descriptive information but cannot prove cause-and-effect relationships. Finally, this is a retrospective report, meaning doctors documented what happened after the fact rather than following a predetermined research protocol.
The Bottom Line
For patients with confirmed FLD: Work closely with specialists (nephrologists for kidneys, cardiologists for heart) to monitor kidney function and watch for heart complications. A restricted diet and blood pressure medications may help slow kidney disease progression in early stages, but regular monitoring is essential to detect when these treatments become less effective. As kidney function declines, increased surveillance for heart rhythm problems, valve disease, and stroke risk is important. Dialysis should be initiated when kidney function reaches appropriate thresholds, as it may improve anemia and remove harmful substances. For family members of FLD patients: Genetic counseling and testing may be appropriate, as this is an inherited condition. Confidence level: Moderate (based on single case report; recommendations should be individualized with medical professionals).
This research is most relevant to: patients with confirmed or suspected FLD, family members of FLD patients, nephrologists and cardiologists treating rare genetic kidney diseases, and genetic counselors. General readers should be aware of this condition primarily if they have a family history of rare kidney disease, unexplained anemia, or eye problems. This is not relevant to the general population, as FLD is extremely rare.
FLD is a progressive disease. In this case, kidney function declined over 10 years before dialysis was needed. However, progression rates vary between patients. Some patients may progress faster or slower. Complications can develop gradually or suddenly. Regular medical monitoring is essential to track disease progression and detect complications early.
Frequently Asked Questions
What is familial lecithin-cholesterol acyltransferase deficiency and how does it damage kidneys?
FLD is a rare inherited genetic disorder where the body cannot properly process cholesterol. This causes cholesterol to accumulate in multiple organs, including the kidneys, leading to progressive kidney damage, anemia, and eye problems. The condition eventually causes kidney failure requiring dialysis.
Can diet and medication slow down kidney disease in FLD patients?
A low-fat, low-protein diet and kidney-protective blood pressure medications may temporarily stabilize kidney function in FLD, but according to this case report, they do not prevent long-term kidney decline. Regular monitoring is essential to detect when these treatments become less effective.
What complications develop as FLD progresses to kidney failure?
This case report shows that as kidney function worsens in FLD, patients may develop serious heart problems including valve disease, dangerous heart rhythms, and heart failure, as well as stroke. These complications appear to result from toxic substances accumulating in the blood.
Does dialysis help FLD patients and what improvements can be expected?
In this case, dialysis led to rapid improvement in anemia that had not responded to other treatments. Dialysis appears to remove harmful uremic toxins that accumulate with kidney failure, though it does not reverse other complications that have already developed.
How often should FLD patients be monitored for complications?
This case suggests FLD patients need regular monitoring of kidney function, heart rhythm, blood pressure, and cardiac symptoms, especially as kidney disease advances. Close surveillance helps detect serious complications early so treatment can be started promptly.
Want to Apply This Research?
- For patients with FLD: Track kidney function markers (creatinine, eGFR) monthly or quarterly, blood pressure daily, heart rhythm symptoms (palpitations, dizziness, fainting), and anemia symptoms (fatigue, shortness of breath). Log any new symptoms affecting vision, heart, or neurological function.
- Patients with FLD should: Adhere strictly to prescribed dietary restrictions (low fat and protein as recommended), take all kidney-protective medications consistently, monitor blood pressure at home, attend all specialist appointments, and immediately report new symptoms like chest pain, fainting, vision changes, or neurological symptoms to their doctor.
- Establish a long-term tracking system that records kidney function tests, blood pressure readings, cardiac symptoms, and any new complications at regular intervals. Share this data with your medical team to help them detect disease progression early and adjust treatment plans accordingly. This is especially important as you transition from early-stage to advanced kidney disease.
This case report describes a single patient’s experience with a rare genetic disease and should not be considered medical advice. Familial lecithin-cholesterol acyltransferase deficiency is extremely rare, and individual cases vary significantly. If you or a family member has symptoms of FLD (eye cloudiness, unexplained anemia, kidney problems) or a family history of this condition, consult with a nephrologist and genetic counselor for proper evaluation and personalized treatment recommendations. This article is for educational purposes only and does not replace professional medical diagnosis or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.